Alexis Desieno Sells 24,778 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 24,778 shares of Cardlytics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the transaction, the chief financial officer now owns 140,948 shares of the company’s stock, valued at approximately $479,223.20. The trade was a 14.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Alexis Desieno also recently made the following trade(s):

• On Friday, January 3rd, Alexis Desieno sold 8,854 shares of Cardlytics stock. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18.

Cardlytics Stock Performance

Shares of NASDAQ CDLX opened at $3.12 on Thursday. The company has a market cap of $158.56 million, a PE ratio of -0.51 and a beta of 1.54. Cardlytics, Inc. has a 12 month low of $2.76 and a 12 month high of $20.52. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.18 and a quick ratio of 1.18. The company has a 50-day simple moving average of $3.45 and a 200-day simple moving average of $3.72.

Institutional Investors Weigh In On Cardlytics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Intech Investment Management LLC grew its holdings in shares of Cardlytics by 31.3% during the fourth quarter. Intech Investment Management LLC now owns 19,310 shares of the company’s stock worth $72,000 after buying an additional 4,607 shares in the last quarter. Check Capital Management Inc. CA grew its holdings in Cardlytics by 10.4% in the third quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock valued at $162,000 after purchasing an additional 4,775 shares during the period. BNP Paribas Financial Markets grew its holdings in Cardlytics by 32.1% in the third quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock valued at $63,000 after purchasing an additional 4,796 shares during the period. SG Americas Securities LLC grew its holdings in Cardlytics by 38.2% in the fourth quarter. SG Americas Securities LLC now owns 19,490 shares of the company’s stock valued at $72,000 after purchasing an additional 5,392 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in Cardlytics by 46.0% in the fourth quarter. Wells Fargo & Company MN now owns 21,106 shares of the company’s stock valued at $78,000 after purchasing an additional 6,649 shares during the period. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CDLX has been the subject of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $6.92.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.